EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repurposed Drugs for Heterotopic Ossification Management: Revitalizing Therapeutic Strategies

Ana Alonso-Pérez iD, Eloi Franco-Trepat iD, María Guillán-Fresco iD, Miriam López-Fagúndez iD, Andrés Pazos-Pérez, Verónica López, Antonio Salas iD, Federico Martinón-Torres iD, Alberto A Jorge-Mora, Rodolfo Gómez iD

Pharmaceuticals · 24.10.2025 · 18 (11) · 1609

DOI: 10.3390/ph18111609 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 24.10.2025. Verfasst von Ana Alonso-Pérez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Musculoskeletal Pathology Group, Laboratory 18, Health Research Institute of Santiago de Compostela (IDIS), Santiago University Clinical Hospital SER…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Fundación Española para la Ciencia y la Tecnología, Fundación Mutua Madrileña.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: Heterotopic ossification (HO) involves abnormal bone growth in soft tissues. Current treatments are ineffective and prone to adverse effects, suggesting the need for new HO therapies. Intramembranous bone growth is led by osteoblasts. Since osteoblastogenesis and adipogenesis are opposed and mutually controlled processes, this study aims to identify a new repurposed therapeutic tool to inhibit osteoblastogenesis through adipogenesis promotion.

Methods

We performed docking experiments between peroxisome proliferator-activated receptor-γ and bone metabolism-affecting drugs, namely, thiazolidinediones (rosiglitazone, pioglitazone), indomethacin, and dexamethasone, to test tritherapy antiosteoblastogenic effect. Mouse mesenchymal stem cells (C3H10T1/2), human osteoblast-like cells (SaOS2 and primary preosteoblasts), and mouse chondrocytes (ATDC5) were differentiated in the presence of these compounds. The effects on osteoblastogenesis, adipogenesis, and endochondral ossification were analysed through marker gene expression via RT–qPCR. Additionally, primary human HO cells and a congenital HO patient were treated with the selected drug combination (P-tritherapy).

Results

Tritherapy significantly and synergistically promoted the expression of an adipogenic marker (fatty acid-binding protein 4) and decreased the expression of an osteoblastogenic marker (osteopontin). In an endochondral ossification model, it reduced ossification markers (collagen-2α1) expression, and in HO cells, it increased adipogenesis markers’ expression. Clinically, P-tritherapy administration prompted bone resorption in a patient with progressive osseous heteroplasia.

Conclusions

Tritherapy induced adipogenesis while inhibiting osteoblastogenesis and endochondral ossification, demonstrating its potential as a new therapeutic tool to prevent abnormal bone growth. These results were consistent with bone turnover modification observed in a congenital HO patient. This concordance underscores tritherapy potential for rapid and safe translation to prevent HO.

Schlagwörter

Stichwörter der Autor:innen

adipocyteboneendochondral ossificationheterotopic ossificationosteoblasttherapy

Autor:innen und Institutionen

  • Musculoskeletal Pathology Group, Laboratory 18, Health Research Institute of Santiago de Compostela (IDIS), Santiago University Clinical Hospital SERGAS, 15706 Santiago de Compostela, Spain.
  • Grupo de Investigación en Genética, Vacunas, Infecciones y Pediatría (GENVIP), Health Research Institute of Santiago de Compostela (IDIS), Santiago University Clinical Hospital SERGAS, 15706 Santiago de Compostela, Spai…
  • Unidade de Xenética, Departamento de Anatomía Patolóxica e Ciencias Forense, Instituto de Ciencias Forenses, Medicine School, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.
  • GenPoB Research Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago University Clinical Hospital SERGAS, 15706 Santiago de Compostela, Spain.
  • Translational Pediatrics and Infectious Diseases, Department of Pediatrics, Santiago University Clinical Hospital SERGAS, 15706 Santiago de Compostela, Spain.
  • Traumatology and Orthopedics Service, SERGAS, A Coruña University Clinical Hospital, 15006 A Coruña, Spain.

ORCID-Profile: Ana Alonso-Pérez, Eloi Franco-Trepat, María Guillán-Fresco, Miriam López-Fagúndez, Antonio Salas, Federico Martinón-Torres, Rodolfo Gómez

Förderung

  • Instituto de Salud Carlos III
  • Fundación Española para la Ciencia y la Tecnología
  • Fundación Mutua Madrileña
  • Ministerio de Universidades
  • Fundación Instituto de Investigación Sanitaria de Santiago de Compostela
  • Axencia Galega de Innovacion
  • Spanish Ministry of Science
  • Mutua Madrileña Foundation

Zitieren

APA

Alonso-Pérez, A., Franco-Trepat, E., Guillán-Fresco, M., López-Fagúndez, M., Pazos-Pérez, A., López, V., Salas, A., Martinón-Torres, F., Jorge-Mora, A. A., & Gómez, R. (2025). Repurposed Drugs for Heterotopic Ossification Management: Revitalizing Therapeutic Strategies. Pharmaceuticals, 18(11), 1609. https://doi.org/10.3390/ph18111609

Vancouver

Alonso-Pérez A, Franco-Trepat E, Guillán-Fresco M, López-Fagúndez M, Pazos-Pérez A, López V, et al. Repurposed Drugs for Heterotopic Ossification Management: Revitalizing Therapeutic Strategies. Pharmaceuticals. 2025;18(11):1609. doi:10.3390/ph18111609

BibTeX
@article{AlonsoPrez2025,
  author = {Alonso-Pérez, Ana and Franco-Trepat, Eloi and Guillán-Fresco, María and López-Fagúndez, Miriam and Pazos-Pérez, Andrés and López, Verónica and Salas, Antonio and Martinón-Torres, Federico and Jorge-Mora, Alberto A and Gómez, Rodolfo},
  title = {Repurposed Drugs for Heterotopic Ossification Management: Revitalizing Therapeutic Strategies},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {11},
  pages = {1609},
  doi = {10.3390/ph18111609}
}
Kostenlos starten →